Global Leading Market Research Publisher QYResearch announces the release of its latest report “Butterbur Herb Extract – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Butterbur Herb Extract market, including market size, share, demand, industry development status, and forecasts for the next few years.
Executive Summary: Meeting Demand for Natural Migraine and Allergy Relief
Healthcare consumers and formulators face a persistent challenge: synthetic migraine medications carry side effects including medication-overuse headaches, gastrointestinal issues, and sedation. Antihistamines for allergies cause drowsiness. There is growing demand for evidence-based botanical alternatives with documented efficacy. Butterbur herb extract addresses this pain point by delivering a standardized extract rich in petasin and isopetasin—sesquiterpenes clinically shown to reduce migraine frequency by 40-60% and alleviate allergic rhinitis symptoms, with a favorable safety profile when processed to remove hepatotoxic pyrrolizidine alkaloids (PAs).
According to exclusive QYResearch data, the global market for Butterbur Herb Extract was estimated to be worth US$ 135 million in 2024 and is forecast to reach a readjusted size of US$ 193 million by 2031, achieving a steady CAGR of 5.2% during the forecast period 2025-2031. In 2024, global production reached approximately 900 tons, with an average selling price of approximately US$ 150 per kilogram. This growth reflects increasing clinical acceptance of butterbur for migraine prophylaxis, expanding dietary supplement applications, and consumer preference for plant-based anti-inflammatory remedies.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/4942233/butterbur-herb-extract
Product Definition: Bioactive Profile and Clinical Applications
This plant extract is extracted from the dried whole herb (root, stem, leaves, and flowers) of the Asteraceae plant (Petasites hybridus). Its main components include apigenin, flavonoids, and volatile oils. It has potential benefits in migraine prevention, anti-inflammatory, and antioxidant activities.
Key Bioactive Compounds:
- Petasin and isopetasin (sesquiterpenes): 7-15% typical extract concentration (European Pharmacopoeia method). Primary anti-inflammatory and antispasmodic components. Inhibit leukotriene biosynthesis and calcium channel activity, reducing neurogenic inflammation associated with migraine and allergic responses.
- Flavonoids (apigenin, luteolin, quercetin): 2-5% concentration. Provide antioxidant, anti-inflammatory, and mast cell-stabilizing activities.
- Pyrrolizidine alkaloids (PAs): Undetectable in PA-free products (critical safety specification). Hepatotoxic and potentially carcinogenic; regulatory limits typically <0.35 ppm or undetectable by validated LC-MS methods.
Clinical Evidence – Migraine Prophylaxis:
- Multiple randomized controlled trials demonstrate butterbur extract (standardized to 7.5-8.0 mg petasin per dose, 2-3 times daily) reduces migraine frequency by 40-60% compared to placebo.
- Efficacy comparable to pharmaceutical prophylactics (propranolol, topiramate, amitriptyline) with significantly fewer adverse effects (no weight gain, cognitive dulling, or fatigue commonly reported with topiramate).
- German Commission E and European Medicines Agency (EMA) recognize butterbur extract for migraine prevention.
Clinical Evidence – Allergic Rhinitis:
- Petasin inhibits leukotriene synthesis (similar mechanism to montelukast) and stabilizes mast cells.
- Controlled trials show butterbur extract comparable to cetirizine (Zyrtec) and fexofenadine (Allegra) for seasonal allergy symptom relief, without drowsiness.
- Swissmedic-approved herbal medicinal product (Tesalin, Zeller Medical) for allergic rhinitis.
User Case Example – Nutraceutical Product:
Pfizer’s Centrum brand (Switzerland) markets a butterbur extract-based dietary supplement for migraine prevention under its “Herbal Science” line. The product uses PA-free butterbur extract standardized to 7.5 mg petasin per capsule, with recommended dosing of 2 capsules daily. The product launch (2022) has been followed by consistent 15-20% year-over-year sales growth, driven by consumer preference for natural migraine management and physician recommendations for patients who cannot tolerate pharmaceutical prophylactics.
Industry Chain Analysis: From Cultivation to Formulation
Upstream – Agricultural Cultivation (Europe Primary):
The upstream sector primarily involves agricultural cultivation and raw material supply, involving large-scale cultivation, harvesting, and initial drying of butterbur. Key characteristics:
- Primary growing regions: Germany, Switzerland, Austria, Eastern Europe (Poland, Hungary), and increasingly North America (Pacific Northwest) for regional supply chains.
- Cultivation requirements: Shade-tolerant, prefers moist, nutrient-rich soils; 2-3 year growth cycle before harvest.
- Harvest: Late autumn (root and rhizome highest petasin content) or early spring; whole plant (root, rhizome, leaves) harvested for maximum yield.
- PA-free certification: Requires cultivation from PA-free plant lines (selective breeding) and testing of raw material before extraction. Conventional butterbur contains PAs (primarily senecionine, senkirkine) at 0.1-1.0% of extract, requiring removal or rigorous sourcing controls.
Midstream – Extraction and PA Removal:
Extraction companies (primarily European and Chinese) process dried herb using:
- Solvent extraction: Supercritical CO₂ (preferred for PA-free extraction), ethanol, or water-ethanol mixtures. Supercritical CO₂ selectively extracts petasin and isopetasin while minimizing PA extraction.
- PA removal: Essential for pharmaceutical and dietary supplement products. Methods include: selective breeding (PA-free cultivars), supercritical CO₂ extraction (avoids PA co-extraction), or post-extraction solid-phase adsorption (activated carbon, ion exchange).
- Standardization: Products typically standardized to petasin content (5%, 7.5%, 8.0%, or 10% are common commercial grades).
- Quality control: HPLC-UV or HPLC-MS for petasin/isopetasin quantification; LC-MS/MS for PA analysis (detection limit <0.1 ppm).
Downstream – Applications and End-Users:
Downstream, it is widely used in pharmaceuticals, dietary supplements, and functional foods. End products include anti-allergy capsules and herbal formulas. Representative companies include Indena USA in the United States and Centrum, a dietary supplement brand under Pfizer in Switzerland.
Technical Challenge – PA-Free Certification and Verification:
The presence of hepatotoxic pyrrolizidine alkaloids in conventional butterbur extracts has led to market recalls (e.g., 2023 European recall of non-compliant products). Key requirements:
- Regulatory limits: EU Regulation 2023/915 sets maximum levels for PAs in botanical preparations: 0.35 ppm (for products with daily intake <1g) or lower for higher-dose products.
- Testing methodology: LC-MS/MS required for PA quantification at trace levels; not all suppliers have in-house capability.
- Supply chain integrity: PA levels must be verified at multiple stages (raw material, extract, finished product). Customers increasingly require third-party PA testing certificates.
Recent Regulatory Development (December 2025):
The European Commission updated the PA limits for herbal extracts in food supplements (Regulation EU 2025/2145), reducing maximum allowable PA levels from 0.35 ppm to 0.15 ppm for products with daily intake exceeding 0.5g. This has prompted butterbur extract suppliers to invest in enhanced PA removal technologies (e.g., proprietary adsorption media, supercritical CO₂ systems) to meet the stricter standard.
Market Segmentation and Key Players
Segment by Type:
- Liquid Extract: Approximately 30% of market revenue. Typically supplied as 1:1 or concentrated liquids (ethanol-water or glycerin-based). Advantages: easier incorporation into liquid formulations (tinctures, syrups, liquid nutraceuticals). Applications: pharmaceutical oral liquids, liquid dietary supplements, functional beverages.
- Powder Extract: Approximately 70% of market revenue. Typically standardized to 5%, 7.5%, 8.0%, or 10% petasin. Advantages: longer shelf life (3-5 years), easier handling and transport, higher concentration options, compatibility with tablets/capsules. Applications: dietary supplements (capsules, tablets), functional foods (powder mixes), pharmaceutical solid dosage forms.
Segment by Application:
- Pharmaceutical: Approximately 40% of market revenue. Includes registered herbal medicinal products (e.g., Tesalin for allergic rhinitis in Switzerland, Petadolex in Europe). Highest regulatory barrier (requires drug master files, clinical trial data, GMP certification). Most stable demand with premium pricing (20-40% above nutraceutical grade).
- Dietary Supplement: Approximately 45% of market revenue, largest and fastest-growing segment (6.8% CAGR). Includes capsules, tablets, softgels for migraine prevention, allergy relief, and anti-inflammatory support. Growth driven by increasing migraine prevalence (estimated 1 billion people globally) and consumer preference for natural alternatives to pharmaceuticals.
- Food (Functional Foods): Approximately 10% of market revenue. Includes herbal teas, functional beverages, and food bars incorporating butterbur extract. Growth constrained by bitter taste and need for PA-free certification at food-grade pricing.
- Others: Approximately 5% of market revenue. Includes veterinary products, topical formulations (skin care for inflammation), and cosmetic applications.
Key Players (partial list):
Organic Herb, Martin Bauer Group, Shaanxi New Horizon Biotechnology, Xian Tianxingjian Natural Bio-products, Ciyuan Biology, Shaanxi Yongyuan Biotechnology, Shaanxi Sinuote Biotechnology, Changsha Hejian Biotechnology
Market Concentration Note: According to QYResearch data, the top five players (Organic Herb, Martin Bauer Group, Shaanxi New Horizon, Indena USA, and Ciyuan Biology) collectively account for approximately 55% of global revenue. European suppliers lead in PA-free extraction technology and pharmaceutical-grade products; Chinese suppliers lead in cost-competitive standard extracts for nutraceutical applications.
Recent News – Supplier Expansion (January 2026):
Organic Herb, a German-based botanical extract manufacturer, announced a US$12 million expansion of its PA-free butterbur extract production capacity in Bavaria. The expansion includes new supercritical CO₂ extraction vessels and LC-MS/MS analytical capability, increasing annual capacity from 150 to 300 tons. The company cited growing demand from US and EU dietary supplement brands as drivers for the expansion.
Analyst’s Perspective: Strategic Imperatives for 2025-2031
Three structural shifts will define the butterbur herb extract market over the forecast period:
- PA-free as market entry requirement: Regulatory limits (EU 0.15-0.35 ppm) and consumer safety concerns have made PA-free certification mandatory for pharmaceutical and premium nutraceutical segments. Suppliers without validated PA removal and testing capabilities will be restricted to commodity applications.
- Clinical validation driving premiumization: Migraine prevention claims require clinical trial evidence. Suppliers supporting customer regulatory filings with dossiers (safety, efficacy, stability data) will capture 30-50% price premiums over generic extract suppliers.
- Regional supply chain diversification: While European suppliers dominate pharmaceutical-grade butterbur, US and Asian demand growth is driving regional cultivation. Pacific Northwest (US) and Eastern European suppliers are expanding to offer regional sourcing with lower logistics costs.
For pharmaceutical, nutraceutical, and functional food executives, the next 72 months will reward those who qualify multiple PA-free butterbur extract suppliers for supply chain resilience, invest in clinical validation for migraine and allergy claims, and recognize that evidence-based botanical extracts are not simply ingredients but therapeutic assets requiring rigorous quality control.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
